Local control in metastatic neuroblastoma in children over 1 year of age

BMC Cancer

Table 2 Univariate analysis of outcome’s predictive factors

		Pts	PFS 5 years	95% CI	Univariate analysis	OS 5 years	95% CI	Univariate analysis
			%		Pvalue	%		Pvalue
Age	12-18 months	11	64	30-85	0.01	73	37-90	0.03
	>18 months	47	19	9-32		28	16-41
Site of Metastasis	Bone/Bone Marrow/Lymph-node	48	25	14-39	0.03	35	22-49	0.03
	Lymph-node alone	3	100	-		100	-
	Others	7	14	1-46		14	1-46
Primary Sites	Retroperitoneal	12	17	3-41	0.28	11	1-38	0.21
	Adrenal Gland	41	28	15-42		40	25-55
	Thorax	5	60	13-88		60	13-88
MYCN	Amplified	19	30	11-52	0.24	26	10-47	0.00
(available for 56 pt)	Non amplified or MYCN gain	37	29	16-44		44	27-59
Induction CT	ICE/CECAT	21	20	6-39	0.59	29	12-48	0.19
	Topo NB	37	33	19-49		40	24-56
Primary Tumor Reduction before Surgery*	<50%	35	22	9-38	0.52	38	21-54	0.43
	>50%, <90%	4	0	-		0	-
	>90%	12	33	10-59		33	10-59
Surgery	Radical	45	26	14-40	0.85	38	23-52	0.42
	Not Radical	13	33	10-59		31	10-55
Response before HDC**	CR/VGPR	21	62	38-79	<0.001	65	40-82	<0.001
	PD	11	0	-		10	1-33
	PR	24	13	3-29		29	13-48
RT	Yes	28	36	19-53	0.23	46	26-64	0.02
	No	30	22	9-38		27	13-43

LEGEND: pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response.
*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.
**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.
Progression-Free Survival and Overall Survival according to predictive factors.

ISSN: 1471-2407